Synergy scores second Phase III success for plecanatide
This article was originally published in Scrip
Executive Summary
Synergy Pharmaceuticals gained 9.2% to reach $8.97 per share in mid-day trading on 30 July based on the second set of positive Phase III data for plecanatide in the treatment of chronic idiopathic constipation (CIC).